Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: History and rationale
- 30 June 2006
- journal article
- review article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 24 (3) , 250-253
- https://doi.org/10.1016/j.urolonc.2005.11.021
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate CancerNew England Journal of Medicine, 2004
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Tumorigenesis and the angiogenic switchNature Reviews Cancer, 2003
- Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2003
- Vessels of Death or LifeScientific American, 2001
- A Phase II Trial of Humanized Anti‐Vascular Endothelial Growth Factor Antibody for the Treatment of Androgen‐Independent Prostate CancerThe Prostate Journal, 2001